Q4 Inc. Announces Restructuring
Q4 Inc. (TSX: QFOR), a leading capital markets communications platform, today announced a restructuring in order to align with market conditions and accelerate its path to profitability, while maintaining the company's steadfast commitment to its clients and delivering the industry’s best customer experience.
This restructuring will result in an 8% reduction of the company's workforce, driving a reduction in operating expenses. It includes the reorganization of various sales and marketing functions, along with a refinement of research and development teams against the company‘s most successful products.
“As we stated in our recent Q2 earnings, in response to current market conditions we are accelerating our path to profitability,” said Darrell Heaps, CEO. “Today’s restructuring is designed to focus our sales, marketing and product teams on the most important areas of our business, where we are able to continue to deliver strong growth with new and existing customers. These changes also enable us to realize significant business efficiencies and reduced operating expenses, driving forward our commitment to be cash flow and EBITDA positive by the second half of 2023. I personally want to thank all of our departing colleagues for their dedication and contributions to Q4. We are grateful we had the opportunity to work together and will support them through this transition.”
This restructuring is effective immediately, and resulting organizational changes have been fully implemented.
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,650 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strong growth, but lower margins for Jotun6.10.2022 21:00:00 CEST | Press release
Jotun increased both operating revenue and operating profit year to date. However, the operating margin was challenged by high raw material prices and significant global unrest. Market status Increased sales volume and prices led to strong topline growth for Jotun during the first and second tertiary 2022. Operating revenue came in at NOK 18 243 million, up 22 per cent from the same period last year. All segments (Decorative Paints, Protective Coatings, Marine Coatings and Powder Coatings) delivered double-digit sales growth. “We are satisfied with the development. It is great to see that the marine newbuilding market has recovered after a difficult period. We also see sales improving within ship maintenance products, protective coatings and decorative paints,” President & CEO Morten Fon says. Global challenges The positive development comes in a time of major global challenges. The war in Ukraine is affecting the raw material markets and creating an energy crisis in Europe. In additio
ProDERM Study Results of octagam ® 10% Treatment in Patients With Dermatomyositis Published in the New England Journal of Medicine6.10.2022 18:33:00 CEST | Press release
Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Efficacy and safety of intravenous immunoglobulin in dermatomyositis”). Dermatomyositis is an immune-mediated myopathy characterised by chronic inflammation of the skin and muscles, leading to cutaneous rashes and progressive muscle weakness. DM is associated with increased morbidity and mortality due to muscle weakness and visceral involvement. Prior to the ProDERM study findings, no therapy had been approved in the US or Europe for the treatment of dermatomyositis based on randomized clinical trials. The Progress in DERMatomyositis (ProDERM) study was the first large randomized clinical trial to investigate an intravenous immunoglobulin (IVIg) (octagam® 10%) in dermatomyositis. The results of the study demonstrated that octaga
New Visa Reports Underscore Importance of Cybersecurity Amid Shifting Threats6.10.2022 17:34:00 CEST | Press release
Visa Inc. (NYSE:V), the world leader in digital payments, today shared an updated look at how fraud has evolved since the height of the pandemic, with criminals simultaneously targeting online and offline vulnerabilities as our daily lives return to a blend of in-person and e-commerce experiences. “As in-person commerce returns to pre-pandemic levels, crooks are back to exploiting the physical points of vulnerability in stores, while continuing to capitalize on e-commerce through malware, ransomware and phishing attacks, among others,” said Paul D. Fabara, Chief Risk Officer at Visa. “In fact, we are continuing to see high rates of skimming, growing over the already elevated levels of the winter of 2021, where fraudsters are jumping on the rise of in-person activity.” Two new pieces of research – the latest Visa Biannual Threats Report and an MIT Technology Review Insights study “Moving Money in a Digital World,” released today in partnership with Visa – highlight new and returning thr
Eurosets Presents Colibrì, the Lightest and Most Compact ECLS System in the Market Which May Be Transported Even in a Backpack6.10.2022 17:24:00 CEST | Press release
Eurosets, a company based in Medolla (Italy) leader in the development, production, and commercialization of advanced medical devices, announced during the 36th European Association for Cardiothoracic Surgery (EACTS) annual meeting (Milan, 5th-8th October 2022) the launch of Colibrì, the lightest extracorporeal life support (ECLS) system available in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005921/en/ Ettore Sansavini, Eurosets President, and Antonio Petralia, Eurosets CEO, next to the Colibrì (Photo: Business Wire) Colibrì complements and expands Eurosets ECLS portfolio with the objective to provide temporary support to patients suffering from ventricular failure, cardiac arrest, or respiratory failure in a variety of different applications, including extracorporeal membrane oxygenation (ECMO), extracorporeal cardiopulmonary resuscitation (E-CPR), and mechanical circulatory support (MCS). Featuring a
Five-Year GSA Contract Expands Raisbeck’s Footprint in Government Arena6.10.2022 16:21:00 CEST | Press release
Raisbeck Engineering, a leading provider of performance enhancement systems for business, commercial and military aircraft, today announced that it has been awarded a General Service Administration Multiple Award Schedule contract (MAS). The contract, which took effect September 30, 2022, is valid for five years with three five-year option periods. The GSA Schedule is significant in that it makes the company’s products accessible through a simplified buying process to state and federal government agencies, expanding the company’s footprint in the federal government marketplace. To qualify for GSA approval, the company went through a rigorous 18-month application process. Contractors selling through the GSA contract are carefully vetted beforehand and must have a proven track record within its industry. The GSA Multiple Award Schedule also provides a competitive advantage in the government sector since terms and conditions including pricing and warranties are previously agreed upon. “We
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom